Angiogenesis is a complex biological process involving the coordinated modulation of many genes. Histone deacetylases (HDAC) are a growing family of enzymes that mediate the availability of chromatin to the transcriptional machinery. Trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA), two HDAC inhibitors known to relieve gene silencing, were evaluated as potential antiangiogenic agents. TSA and SAHA were shown to prevent vascular endothelial growth factor (VEGF)-stimulated human umbilical cord endothelial cells (HUVEC) from invading a type I collagen gel and forming capillary-like structures. SAHA and TSA inhibited the VEGF-induced formation of a CD31-positive capillary-like network in embryoid bodies and inhibited the VEGF-induced angiogenesis in the CAM assay. TSA also prevented, in a dose-response relationship, the sprouting of capillaries from rat aortic rings. TSA inhibited in a dose-dependent and reversible fashion the VEGF-induced expression of VEGF receptors, VEGFR1, VEGFR2, and neuropilin-1. TSA and SAHA upregulated the expression by HUVEC of semaphorin III, a recently described VEGF competitor, at both mRNA and protein levels. This eect was speci®c to endothelial cells and was not observed in human ®broblasts neither in vascular smooth muscle cells. These observations provide a conspicuous demonstration that
Introduction
Histone deacetylases (HDAC) are pleiotropic enzymes involved in the general control of the acetylation of histones and in the accessibility of DNA to the transcriptional machinery (Struhl, 1998) . It is therefore noteworthy that their inhibition generates speci®c phenotypes rather than cell chaos. There are now numerous examples demonstrating that some HDAC are recruited by transcription repressors to silence speci®c genes (Struhl, 1998) . The interactions of the HDAC with these repressors could be the basis for the diversity and selectivity of the biological responses resulting from their inhibition. The blocking of HDAC activity by a variety of inhibitors, including trichostatin-A (TSA) (Yoshida et al., 1990) , suberoylanilide hydroxamic acid (SAHA) (Richon et al., 1998) and trapoxin (TPX) (Kijima et al., 1993) , modulates the dierentiation of normal and malignant cells. TSA suppresses Ras-induced neurite outgrowth of PC12 cells (Futamura et al., 1995) , induces dierentiation of AML1-ETO leukemia cells (Wang et al., 1999) , enhances beta retinoic acid receptor expression in epithelial cells (Arapshian et al., 2000) and prevents myo®broblastic dierentiation of rat hepatic stellate cells (Niki et al., 1999) . Inhibition of HDAC also forces cancer cells to undergo apoptosis (Glick et al., 1999) and causes signi®cant suppression of human prostatic tumor growth in nude mouse (Butler et al., 2000) . The lack of apparent toxicity of TSA and SAHA in vivo (Nervi et al., 2001; Butler et al., 2000) , support the HDAC inhibitors as potential valid therapeutic agents.
Angiogenesis is a complex biological process involving the coordinated modulation of many genes encoding proteins sequentially required for the formation of functional capillaries. Alterations of this precise scheme of gene activation by their silencing could block angiogenesis. The various steps required for angiogenesis can be induced in in vitro and ex vivo models by using drugs as tetradecanoyl phorbol acetate (TPA) or cytokines such as ®broblast growth factor (FGF) -1, -2 or vascular endothelial growth factor (VEGF) (for review, see Pepper et al., 1996) .
In this study, we investigated the eect of HDAC inhibitors in dierent models of angiogenesis, spontaneous or induced by VEGF, a cytokine playing a determinant role in physiological and tumoral angiogenesis (Neufeld et al., 1999) and determined a molecular mechanism of action altering VEGF signaling. At the time that we were preparing this manuscript, a study reporting the involvement of histone deacetylases in angiogenesis was published by Kim et al. (2001) . Their data, while supporting our ®nding of potential anti-angiogenic activities for HDAC inhibitors, explored another mechanism of action of HDAC, e.g. the p53 pathway.
Results

In vitro antiangiogenic properties of HDAC inhibitors
The eect of TSA was ®rst tested in two in vitro procedures in which endothelial cells are stimulated to form capillary-like structures. In the ®rst assay (`invading angiogenic assay'), human umbilical vein endothelial cells (HUVEC) were cultured at the surface of a type I collagen gel. In control medium, HUVEC spread and proliferated to display, at con¯uence, a typical cobblestone-like morphology without invading the collagen gel ( Figure 1a) . In parallel cultures of HUVEC treated daily with recombinant human vascular endothelial growth factor (rhVEGF), cells progressively lost their uniform morphology and became spindle shaped (Figure 1b) . After 4 ± 6 days of culture with rhVEGF, a signi®cant number of cells had migrated into the underlying gel and organized into branching capillary-like structures (Figure 1c) as previously described (Deroanne et al., 1997) . At 100 nM, TSA suppressed the rhVEGF-induced capillary-like structures formation without altering the acquisition of a spindle-shaped morphology (Figure 1d ). At 400 nM, TSA suppressed the rhVEGF-induced spindle-shaped pattern (Figure 1e ), and the HUVEC maintained their cobblestone-like morphology for up to 10 days. The inhibitory eect of TSA was reversible as the VEGF-activated HUVEC treated for 4 days with 400 nM TSA recovered an angiogenic morphotype upon withdrawal of the inhibitor (Figure 1f ). The other tested HDAC inhibitors, SAHA (5 mM) and TPX (100 nM), similarly inhibited the VEGF-induced angiogenic morphotype (data not shown). The experiments were performed at least three times for each condition and generated reproducible data. A signi®cant increase of the acetylation level of histone H4, as evaluated by Western blot, was observed in HUVEC treated with 400 nM TSA (data not shown).
In the second in vitro assay, the endothelial cells are cultured between two collagen gels. In these conditions, the HUVEC organized into a network of tube-like structures and became quiescent (Deroanne et al., 1996) . This model is considered as representative of the last phase of angiogenesis, i.e. vessel maturation (Pepper et al., 1996) . HUVEC cultured for 2 days in this model in medium containing 400 nM TSA organized into tubelike structures as eciently as control cells treated with the vehicle alone (Figure 1g, h ).
HDAC inhibitors repress vessels formation in the embryoid body, in the rat aortic ring and in the chick chorioallantoic membrane assays
The antiangiogenic properties of histone deacetylase inhibitors were also tested on attached embryoid bodies (EB). This model mimics both vasculogenesis and angiogenesis. Capillary-like structures formation was analysed by the expression of CD31 in whole mount immuno¯uorescence as reported by Vittet et al. (1996) . A signi®cant inhibition of the angiogenic phenotype was observed in the presence of 4 and 10 nM TSA as well as 0.4 mM and 1 mM SAHA ( Figure 2 and Table 1 ). In these conditions, the number of CD31-positive cells was strongly reduced and the few positive cells were mostly isolated or barely organized. None of the inhibitors displayed an overall toxic eect on EB as their growth and morphology were not signi®cantly altered as illustrated by the DAPI staining in Figure 2 . Moreover, in all tested conditions, the EB were beating at the end of the culture period, suggesting that the dierentiation and function of the other types of cell, i.e. cardiomyocytes, were not impaired.
The antiangiogenic properties of TSA were con®rmed in the ex vivo rat aortic ring assay (Nicosia and Ottinetti, 1990) , in which the addition of increasing concentrations of TSA progressively inhibited the spontaneous outgrowth of endothelial cells ( Table 2 ). The experiments were performed at least three times for each condition and generated reproducible data.
Modulated expression of specific genes in HUVEC treated with HDAC inhibitors
The eect of TSA on the phenotype of HUVEC was further evaluated by measuring the steady-state level of the mRNAs coding for the VEGF receptors, VEGFR1, its soluble form sVEGFR1, VEGFR2 (Neufeld et al., 1999) , and the recently identi®ed co-receptor for VEGF165, neuropilin-1 (Miao et al., 1999) . The mRNA level of two proteins that are modulated during in vitro VEGF-induced angiogenesis, the type I collagen-degrading enzyme (MMP1) and its physiological inhibitor (TIMP1) (Deroanne et al., 1997) was also measured. Total RNA was obtained from HUVEC cultured in the invading in vitro angiogenic assay described above and analysed by Northern blot. Under control conditions, the steady-state level of the mRNAs coding for the VEGF receptors and for MMP1 was low ( Figure 4a , lane 1). VEGF strongly enhanced the mRNA steadystate level of the three VEGF receptors including neuropilin-1 and that of MMP1 ( Figure 4a , lane 2). Treatment of HUVEC with 100 nM TSA, a concentration that inhibited the invading phenotype without altering the spindle-shaped morphology of HUVEC, induced a 50% decrease of the VEGFinduced overexpression of VEGFR2 mRNA without any signi®cant eect on the expression of VEGFR1, sVEGFR1, or neuropilin-1 (Figure 4a , lane 3). At 400 nM TSA, the VEGF-induced overexpression of the VEGF receptors, including neuropilin-1 was signi®cantly reduced. This downregulation did not result from an overall repression of transcription since the VEGF-driven MMP1 overexpression as well as the mRNA levels of TIMP1 and b-actin were not signi®cantly aected by 400 nM TSA ( Figure 4a ). Withdrawal of TSA reversed its eects on the VEGF receptors expression (Figure 4b , lanes 3 and 4). Treatment of HUVEC with 100 nM TPX similarly inhibited the rhVEGF-induced overexpression of the VEGF receptor genes (not shown).
HDAC inhibitors-induced upregulation of semaphorin III expression in endothelial cells
Our ®nding that TSA downregulated the VEGF-induced expression of VEGF receptors was unexpected and suggested an indirect eect of the drug. We therefore explored the possibility that TSA treatment could aect the expression of semaphorin III, a recently described VEGF competitor (Miao et al., 1999) . By Northern blot analysis, we observed that TSA at 400 nM reversibly induced the expression of semaphorin III mRNA ( Figure  4c ). Using a quantitative RT ± PCR assay, we demonstrated that TSA signi®cantly increased the semaphorin III mRNA level in HUVEC already at 40 nM and by 20-fold at 400 nM whether in the presence or absence of VEGF (Figure 5a,b) . A signi®cant induction of semaphorin III mRNA was also observed in HUVEC treated with SAHA at concentrations ranging from 1 to 10 mM (Figure 5c ). This up-regulation was restricted to endothelial cells since TSA and SAHA did not aect the semaphorin III mRNA expression in human skin ®broblasts (Figure 5d ± f) . TSA did not modify the semaphorin III mRNA expression in human smooth muscle cells neither in MDA-MB231 (not shown). Finally, Western blot analysis of medium conditioned Figure 1 (a ± f), inhibition of in vitro angiogenesis by TSA. Phase-contrast microscopy photographs of HUVEC cultured on a type I collagen gel for 8 days in (a) RPMI or (b) RPMI supplemented with rhVEGF (25 ng/ml) to induce angiogenesis. (c) same ®eld as in (b) but focused on a branching capillary-like structure that has invaded the gel. (d ± f), Reversible inhibition of angiogenesis by TSA. Cells were cultured in RPMI supplemented with (d) rhVEGF and TSA (100 nM) (e) with rhVEGF and TSA (400 nM) and (f) with rhVEGF and TSA (400 nM) until day 4 and with rhVEGF alone from day 5 to day 8. In (f) the photograph is focused on a branching capillary-like structure within the collagen gel. Phase-contrast microscopy photographs of HUVEC cultured between two collagen gels (g and h). The collagen-induced tube-like structures are not inhibited by TSA. HUVEC cultured with vehicle alone (g) or 400 nM TSA (h). Representative results of at least three separate experiments are shown. Bars=25 mm by HUVEC treated with TSA, SAHA or vehicle alone demonstrated the induction of semaphorin III expression at the protein level by both HDAC inhibitors ( Figure 6 ). Semaphorin III was detected at the expected size of 100 kD, as reported by Miao et al. (1999) .
Discussion
Antiangiogenic therapy of cancers oers the possibility of a low toxicity treatment without acquisition of drug resistance due to the genetic stability, homogeneity and low mutational rate of endothelial cells (Boehm et al., 1997) . Angiogenesis is a complex biological process involving the coordinated modulation of many genes. A precise sequence of activation and inhibition of speci®c genes is required for the formation, maturation and maintenance of functional capillaries. It represents therefore an interesting target to block tumoral progression and metastatic spreading. In this study, we observed that the angiogenic morphotype and gene expression of endothelial cells were modulated by inhibiting the activity of the histone deacetylases (HDAC), a family of enzymes involved in the control of the accessibility of DNA to the transcriptional machinery (Struhl, 1998) . By using speci®c inhibitors, mainly TSA and SAHA (Yoshida et al., 1990; Richon et al., 1998) in dierent models based on in vitro, ex vivo and in vivo assays, we demonstrated that HDAC inhibition suppresses the spontaneous or VEGFinduced angiogenesis. The low toxicity of TSA is supported by the reversibility of its eect in our in vitro angiogenic assays. Moreover, SAHA and TSA inhibit the formation of a capillary-like network in the embryoid bodies without altering the growth, dierentiation and function of other cell types i.e. the cardiomyocytes. These observations are in agreement with recent studies reporting the low toxicity of TSA in vivo (Nervi et al., 2001) . Interestingly, TSA did not alter the morphology of quiescent endothelial cells in the tubulogenic assay (Deroanne et al., 1996) further supporting its low toxicity and suggesting that the drug only targets activated endothelial cells and could speci®cally alter the developing tumoral vasculature. The non toxicity of TSA is further supported by the recent study of Kim et al. (2001) who report that 330 nM TSA did not decrease thymidine incorporation in bovine aortic endothelial cells in normoxia.
Our data demonstrated that the inhibition of HDAC suppresses angiogenesis likely by preventing endothelial cells from responding to the angiogenic stimulus generated by VEGF. The VEGF-induced overexpression of VEGFR1 and VEGFR2 (Neufeld et al., 1999; Shen et al., 1998) creates a loop allowing endothelial cells to become responsive and activated. This loop represents a signi®cant target for therapeutic intervention (Angelov et al., 1999) . In this work, we further demonstrated that the VEGF co-receptor, neuropilin-1, was similarly up-regulated by VEGF. The inhibition of VEGF-induced overexpression of VEGFR1, VEGFR2 and neuropilin-1 by TSA supports the potentialities of HDAC inhibition as an antiangiogenic tool. Furthermore, the reduction of the expression of neuropilin-1 by TSA can also contribute to repress angiogenesis by depressing cell migration (Shimizu et al., 2000) . The expression of the mRNA coding for MMP1, a protease required for degradation of the collagen gel in the in vitro angiogenic assay, and its physiological inhibitor TIMP1 (Fisher et al., 1994 , Deroanne et al., 1997 were not altered by TSA or TPX. It indicates that the HDAC inhibitors did not act through a general repression of transcription and, as an accessory conclusion, that the VEGF-induced overexpression of MMP1 is not sucient to sustain the angiogenic process.
HDAC have been associated with a repression of transcription (Struhl, 1998) and their inhibition should relieve gene silencing. Our observation that HDAC inhibitors downregulated the expression of VEGF receptors suggested the existence of an indirect mechanism. Semaphorin III/collapsin-1 was recently found to inhibit angiogenesis as a competitive inhibitor of the interaction between the VEGF165 This table summarizes the results of three independent experiments. EB were positive when a CD31-positive network was organized on at least 25% of their surface. At the two highest concentrations of TSA and SAHA, the capillary-like network in the few positive EB did not cover the whole EB as it was observed in control positive EB (see Figure 2 ) splice variant and neuropilin-1 (Miao et al., 1999) . Semaphorin III also inhibits endothelial cell motility in vitro as well as the sprouting of capillaries from rat aortic rings (Miao et al., 1999) . Our ®nding that TSA and SAHA induce the expression of semaphorin III in endothelial cells at both mRNA and protein levels can account for the anti-angiogenic properties of these compounds by blocking the VEGF-induced expression of the VEGF receptors and the angiogenic loop.
Speci®c competitors of the binding of VEGF to its receptor have been shown to prevent angiogenesis induced in the early stages of tumoral development and metastases formation (Shaheen et al., 1999) pointing to the potentialities of HDAC inhibitors in the treatment of cancer. Nevertheless, other mechanisms mediating TSA and SAHA inhibition of VEGF signaling cannot be totally excluded. Since the completion of this work, an additional mechanism involving an up-regulation of p53 and von Hippel ± Lindau genes in hypoxic conditions by TSA has been described (Kim et al., 2001) . However, this mechanism is unlikely to be involved in the TSA and SAHAmediated alteration of VEGF signaling reported here since our experiments were conducted in normoxia.
Moreover, RT ± PCR measurements did not reveal any signi®cant modulation of VHL mRNA expression by 400 nM TSA in HUVEC (data not shown). Our observations and those of Kim et al. (2001) are complementary: they reported the involvement of HDACs in hypoxia-induced VEGF expression, we observed an alteration of VEGF signaling induced by two HDAC inhibitors that involved semaphorin III. At least two studies have reported that HDAC inhibitors suppress tumor growth in animal models (Butler et al., 2000 , Kim et al., 2001 . Kim et al. (2001) showed that TSA inhibited the growth of Lewis lung carcinoma when injected into tumor bearing mice. This eect was, at least in part, due to an inhibition of angiogenesis. Butler et al. (2000) treated nude mice bearing human prostate tumors with SAHA and observed a signi®cant reduction of tumor growth. HDAC inhibitors induced the apoptosis of cancer cells. It is therefore not easy to state clearly which is the main mechanism leading to tumor regression. The data reported by Kim et al. (2001) as well as those presented in this study support a signi®cant role to the anti-angiogenic activities of HDAC inhibitors in their control of tumor growth. The lack of induction of semaphorin III expression by HDAC inhibitors in ®broblasts, smooth muscle cells and MDA-MB231 suggests the existence of a speci®c transcription repressor complex recruiting HDACs to silence semaphorin III gene in endothelial cells. The identi®cation of the endothelial-speci®c elements of this repressor complex could oer new approaches to antiangiogenic therapy not only in cancer but also in a variety of diseases, characterized by an excessive angiogenesis.
Material and methods
In vitro angiogenic assay
The in vitro angiogenic assay was performed essentially as previously described (Deroanne et al., 1997) . Brie¯y, HUVEC were suspended in RPMI 1640 medium containing 5% fetal calf serum (FCS) and 5% heat-decomplemented pooled human serum (HDS) and seeded (6610 4 cells/cm 2 ) on a 0.4-mm- thick collagen gel made of RPMI 1640 medium containing 1 mg/ml of puri®ed bovine type I collagen polymerized for 10 min at 378C (Deroanne et al., 1996) . After cell spreading, invasion of the collagen gel and formation of tube-like structures were induced by adding rhVEGF (25 ng/ml) (Sigma, V7259). Various concentrations of the HDAC inhibitor TSA (Sigma, T8552), SAHA (Calbiochem, 559301), TPX or the vehicle alone, were added simultaneously to rhVEGF. Culture medium, In vitro tubulogenic assay HUVEC were induced to organize into a network of tube-like structures as described (Deroanne et al., 1996 (Deroanne et al., , 2001 . Brie¯y, the cells were seeded (4610 4 cells/cm 2 ) on a 0.4-mm-thick collagen gel. After spreading, the cells were covered with a similar collagen gel. RPMI 1640 medium supplemented with 5% FCS and 5% HDS containing 400 nM TSA or vehicle alone was added after polymerization of the covering gel.
ES cells and embryoid bodies
Undierentiated ES CGR8 cells (a kind gift of C. Dani, CNRS-UMR6543, Nice, France) were cultured on gelatin-coated dishes in DMEM supplemented with 10% FCS, 0.1 mM non-essential amino acids, 0.1 mM b-mercaptoethanol and leukemia inhibitory factor (LIF). 800 ES cells were aggregated by culture on bacteriological dishes during 4 days in a 20 ml drop of the same medium without LIF but supplemented with 25 ng/ml of VEGF to optimize the dierentiation into endothelial cells. The aggregates were seeded on gelatin-coated glass coverslips in the same medium supplemented with TSA, SAHA or vehicle alone, the medium and the inhibitors being renewed every 48 h for 8 days. The embryoid bodies (EB) were ®xed in methanol at 7208C for 15 min, air-dried and washed three times in PBS. For labeling, EB were incubated for 45 min with anti-CD31 antibody (Pharmingen, 01951D, 1 : 500) at room temperature, washed three times in PBS, incubated for 30 min with a biotinconjugated donkey anti-rat IgG antibody (Jackson ImmunoResearch, 1 : 500) , washed three times in PBS and incubated for 30 min with both Alexa Fluor 594-conjugated streptavidin (Molecular Probes, S-11227, 1 : 500) and DAPI (Roche, 236276, 1 mg/ml). Immuno¯uorescence was analysed with a Leica DM-R microscope equipped with a DC-100 digital camera.
Rat aortic ring assay
The rat aortic ring assay was based on the model of Nicosia and Ottinetti (1990) . In brief, thoracic aortas were removed from 8-to 12-week-old male Fisher-344 rats. The ®broadipous tissue was carefully removed and the aortas were cut into 1-mm rings. Ring-shaped aortic explants were embedded in rat tail tendon collagen (1.5 mg/ml) polymerized in cylindrical agarose wells. The culture medium MCDB131 was supplemented with 25 mM NaHCO 3 . The cultures were kept at 378C in a humidi®ed 5% CO 2 incubator and examined by phase contrast microscopy after 7 to 9 days. Aortic rings were treated with TSA or vehicle alone in the presence or absence of rhVEGF (25 ng/ml). Quanti®-cation of vessels outgrowth was performed as described (Blacher et al., 2001) .
Chick chorioallantoic membrane (CAM) assay
The chicken CAM assay was performed as previously described (Ribatti et al., 1997) . Brie¯y, fertile Lohman-selected white Leghorn eggs were incubated at 378C in a humidi®ed incubator. At day 3 of development, a rectangular window was opened in the egg shell. At day 8, two Silastic rings were placed on the surface of the CAM. TSA (60 and 600 ng) in sterile phosphate buered saline (PBS) was applied in 5-ml inside the rings. PBS alone and recognized inhibitors of angiogenesis, (hydrocortisone (60 mg/ml) and heparin (50 mg/ml) (1 : 1)) were used as controls. CAM were examined daily until day 10 and photographed in ovo. For each condition, at least ®ve eggs were treated, and the experiments were performed at least ®ve times.
Northern blot analysis
Total RNA was extracted from the HUVEC, puri®ed and subjected to Northern blot analysis as described (Deroanne et al., 1997) . Human probes were fragments of human VEGF receptor (VEGFR)-1 cDNA (nucleotides 384 ± 883 in the open reading frame (ORF)), human VEGFR-2 cDNA (nucleotides 441 ± 903 in the ORF), and human neuropilin-1 cDNA (nucleotides 66 ± 465 in the ORF). Human probe for semaphorin III was a full-length cDNA (a kind gift of M TessierLavigne, UCSF, San Francisco, CA, USA). Human probes for MMP1, TIMP-1 and b-actin were used as previously described (Deroanne et al., 1997) . The 28S rRNA was hybridized with an end-labeled oligonucleotide (Promega) according to the manufacturer's instructions. In some experiments, membranes were prehybridized and hybridized with ULTRAhyb 1 (Ambion) hybridization mix according to the manufacturer's instructions.
Quantitative RT ± PCR
The RT ± PCR ampli®cations were performed in an automated thermocycler (GeneAmp PCR system 2400 using a GeneAmp Thermostable rTth Reverse Transcriptase RNA PCR kit, Perkin Elmer) with two dierent pairs of primers amplifying human semaphorin III mRNA (5'-GCTAGAATAGGTCAGATA-TGCAAGAA-3' and 5'-GCATATGGACCAAGGAA-CACCCTT-3'), human VHL mRNA (5'-CGCATC-CACAGCTACCGAGGTCA-3' and 5'-CCTGACGA- TGTCCAGTCTCCTGTA-3' and 28S rRNA (5'-GT-TCACCCACTAATAGGGAACGTGA-3' and 5'-GG-ATTCTGACTTAGAGGCGTTCAGT-3'). For semaphorin III and the 28S rRNA, the eciency of the RT ± PCR was controlled by a synthetic RNA cotranscribed and co-ampli®ed with the same primers. For semaphorin III, the synthetic RNA generated a 218-bp product while the endogenous mRNA generated a 284-bp product. For the 28S rRNA, the synthetic RNA generated a 269-bp product while the endogenous RNA generated a 212-bp product. For quantitative RT ± PCR measurements, 10 ± 20 ng of total RNA and a known copy number of the standard synthetic RNA were used per 25 ml reaction mixture (®nal volume). The RT step (708C for 15 min) was followed by a 2-min incubation at 948C, for denaturation of RNA-DNA heteroduplexes, and then by ampli®cation for 36 cycles (semaphorin III in HUVEC) 30 cycles (VHL in HUVEC and semaphorin III in skin ®broblasts) or 19 cycles (28S rRNA). The PCR conditions were 948C for 15 s, 668C for 20 s and 728C for 20 s (semaphorin III) or 10 s (28S rRNA). The PCR products were quanti®ed after electrophoresis on a 10% polyacrylamide gel and staining (Gelstar, FMC BioProducts) using a Fluor-S TM MultiImager (Bio-Rad Laboratories, Life Science). The signals of the endogenous mRNA and 28S rRNA were normalized to the signals generated by the synthetic RNA and the results of semaphorin III expressed as arbitrary units per unit of 28S rRNA.
Western blot analysis
Con¯uent HUVEC in 10 cm tissue culture dishes were treated with TSA, SAHA or vehicle alone during 24 h. Cells were then rinsed and 4 ml of RPMI supplemented with 100 mg/ml BSA and TSA, SAHA or vehicle alone were conditioned during 24 h. The conditioned media (CM) were concentrated by centrifugation on Ultrafree-4 Centrifugal Filter Unit (Millipore). Half of each concentrated CM were electrophoresed under reducing conditions on a 6% SDS-polyacrylamide gel and subsequently electrotransferred onto a polyvinylidene di¯uoride membrane (Immobilon-P, Millipore). The membrane was incubated for 6 h at 48C with a goat polyclonal anti-semaphorin III antibody (SC-1146, Santa Cruz) and subsequently with a peroxidase-conjugated rabbit antigoat IgG antibody (Dako, P0449). Peroxidase was revealed by the enhanced chemiluminescence (ECL) system.
